Evidence map›Paper›PMID 39019846›Full record

ArticleNature communications2024

Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation.

Sonia J Laurie, Joseph P Foster, Danny W Bruce, Hemamalini Bommiasamy, Oleg V Kolupaev, Mostafa Yazdimamaghani, Samantha G Pattenden, Nelson J Chao, Stefanie Sarantopoulos, Joel S Parker and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sonia J Laurie *Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0003-1509-6407
Joseph P Foster *Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Danny W BruceLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Hemamalini BommiasamyLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Oleg V KolupaevLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Mostafa YazdimamaghaniLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Samantha G PattendenCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Nelson J ChaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.ORCID 0000-0001-6725-7220
Stefanie SarantopoulosDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.ORCID 0000-0003-4551-6687
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0003-2080-6901
Ian J DavisLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Jonathan S SerodyLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA. jonathan_serody@med.unc.edu.ORCID 0000-0003-4568-1092

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
SEEDING POSTDOCTORAL INNOVATORS IN RESEARCH &EDUCATIONK12GM000678 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DONALD T LYSLE, Kathryn Joanna Reissner · 1999 to 2026
$30.9M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.R01HL155098 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan S. Serody · 2021 to 2026
$3.5M
UNC Predoc Training Progr in Bioinformatics/Comp BiologyT32GM067553 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELSTON, TIMOTHY C · 2005 to 2019
$2.5M
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHDR01HL139730 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2017 to 2020
$2.2M
Duke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2M
Developmental control of chromatin states in cancerR01CA276663 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian J Davis · 2023 to 2026
$1.7M
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical researchR01GM138912 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, IAN J, PATTENDEN, SAMANTHA GAIL · 2021 to 2024
$1.7M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA276663NCI NIH HHS T32 CA196589NCI NIH HHS T32 CA211056NHLBI NIH HHS R01 HL139730NHLBI NIH HHS R01 HL155098NIAID NIH HHS P30 AI050410NIDDK NIH HHS P30 DK034987NIEHS NIH HHS P30 ES010126NIGMS NIH HHS K12 GM000678NIGMS NIH HHS R01 GM138912NIGMS NIH HHS T32 GM067553U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1T32CA211056-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA276663U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) 1R01HL139730-03U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) 1R01HL155098-01A1U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 1K12GM000678-20U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM138912U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM067553
6 · The paper itself

Abstract

Type II innate lymphoid cells (ILC2s) maintain homeostasis and barrier integrity in mucosal tissues. In both mice and humans, ILC2s poorly reconstitute after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Determining the mechanisms involved in their impaired reconstitution could improve transplant outcomes. By integrating single-cell chromatin and transcriptomic analyses of transplanted ILC2s, we identify a previously unreported population of converted ILC1-like cells in the mouse small intestine post-transplant. Exposure of ILC2s to proinflammatory cytokines resulted in a mixed ILC1-ILC2 phenotype but was able to convert only a small population of ILC2s to ILC1s, which were found post-transplant. Whereas ILC2s protected against acute graft-versus-host disease (aGVHD) mediated mortality, infusion of proinflammatory cytokine-exposed ILC2s accelerated aGvHD. Interestingly, murine ILC2 reconstitution post-HSCT is decreased in the presence of alloreactive T cells. Finally, peripheral blood cells from human patients with aGvHD have an altered ILC2-associated chromatin landscape compared to transplanted controls. These data demonstrate that following transplantation ILC2s convert to a pro-pathogenic population with an ILC1-like chromatin state and provide insights into the contribution of ILC plasticity to the impaired reconstitution of ILC2 cells, which is one of several potential mechanisms for the poor reconstitution of these important cells after allo-HSCT.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunity, InnateLymphocytesMice, Inbred C57BLTransplantation, HomologousAnimalsCell PlasticityChromatinCytokinesFemaleHumansIntestine, SmallMaleMiceMice, Inbred BALB CChromatinCytokines

Identifiers

PMID39019846
PMCPMC11255294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.